New literature on Palmitoylethanolamide, published in 2013, 60 PubMed indexed articles

1.
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.
Sałaga M, Sobczak M, Fichna J.
Eur J Pharm Sci. 2013 Nov 23. doi:pii: S0928-0987(13)00451-X. 10.1016/j.ejps.2013.11.012. [Epub ahead of print]

2.
Endocannabinoid signalling in Alzheimer’s disease.
Maroof N, Pardon MC, Kendall DA.
Biochem Soc Trans. 2013 Dec 1;41(6):1583-7. doi: 10.1042/BST20130140.

3.
Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice.
Impellizzeri D, Esposito E, Di Paola R, Ahmad A, Campolo M, Peli A, Morittu VM, Britti D, Cuzzocrea S.
Arthritis Res Ther. 2013 Nov 18;15(6):R192. [Epub ahead of print]

4.
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P.
Inflammopharmacology. 2013 Nov 1. [Epub ahead of print]

5.
The endocannabinoid system mediates aerobic exercise-induced antinociception in rats.
Galdino G, Romero TR, Silva JF, Aguiar DC, de Paula AM, Cruz JS, Parrella C, Piscitelli F, Duarte ID, Di Marzo V, Perez AC.
Neuropharmacology. 2013 Oct 19;77C:313-324. doi: 10.1016/j.neuropharm.2013.09.022. [Epub ahead of print]

6.
Brain Region-Specific Changes in N-Acylethanolamine Contents with Time of Day.
Liedhegner ES, Sasman A, Hillard CJ.
J Neurochem. 2013 Oct 18. doi: 10.1111/jnc.12495. [Epub ahead of print]

7.
Plasma anandamide and related n-acylethanolamide levels are not elevated in pregnancies complicated by hyperemesis gravidarum.
Gebeh AK, Willets JM, Marczylo TH, Konje JC.
J Matern Fetal Neonatal Med. 2013 Oct 22. [Epub ahead of print]

8.
Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation.
Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, Cuomo R, Sarnelli G, Steardo L.
Gut. 2013 Sep 30. doi: 10.1136/gutjnl-2013-305005. [Epub ahead of print]

9.
Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold.
Keppel Hesselink JM, de Boer T, Witkamp RF.
Int J Inflam. 2013;2013:151028. Epub 2013 Aug 27. Review.

10.
[Administration of micronized palmitoylethanolamide (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results].
Lo Monte G, Soave I, Marci R.
Minerva Ginecol. 2013 Aug;65(4):453-63. Italian.

11.
Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection.
Keppel Hesselink JM.
Int Med Case Rep J. 2013 Sep 13;6:49-53. doi: 10.2147/IMCRJ.S51572.

12.
Mast cells, glia and neuroinflammation: partners in crime?
Skaper SD, Facci L, Giusti P.
Immunology. 2013 Sep 11. doi: 10.1111/imm.12170. [Epub ahead of print]

13.
Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors.
Ponzano S, Bertozzi F, Mengatto L, Dionisi M, Armirotti A, Romeo E, Berteotti A, Fiorelli C, Tarozzo G, Reggiani A, Duranti A, Tarzia G, Mor M, Cavalli A, Piomelli D, Bandiera T.
J Med Chem. 2013 Sep 12;56(17):6917-34. doi: 10.1021/jm400739u. Epub 2013 Aug 30.

14.
Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical.
Keppel Hesselink JM.
J Pain Res. 2013 Aug 8;6:625-34. doi: 10.2147/JPR.S48653. eCollection 2013.

15.
N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress.
Mattace Raso G, Simeoli R, Russo R, Santoro A, Pirozzi C, d’Emmanuele di Villa Bianca R, Mitidieri E, Paciello O, Pagano TB, Orefice NS, Meli R, Calignano A.
Pharmacol Res. 2013 Oct;76:67-76. doi: 10.1016/j.phrs.2013.07.007. Epub 2013 Aug 2.

16.
[Pharmacological therapy of temporomandibular joint pain].
Hugger A, Schindler HJ, Türp JC, Hugger S.
Z Evid Fortbild Qual Gesundhwes. 2013;107(4-5):302-8. doi: 10.1016/j.zefq.2012.12.003. Epub 2013 Jan 11. German.

17.
Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence.
Coppola M, Mondola R.
Med Hypotheses. 2013 Oct;81(4):619-22. doi: 10.1016/j.mehy.2013.07.016. Epub 2013 Jul 26.

18.
A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury.
Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E.
J Neuroinflammation. 2013 Jul 23;10:91. doi: 10.1186/1742-2094-10-91.

19.
Fatty acid ethanolamides modulate CD36-mRNA through dietary fatty acid manipulation in Syrian Golden hamsters.
Lin L, Rideout T, Yurkova N, Yang H, Eck P, Jones PJ.
Appl Physiol Nutr Metab. 2013 Aug;38(8):870-8. doi: 10.1139/apnm-2012-0289. Epub 2013 Mar 14.

20.
Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression.
Crupi R, Paterniti I, Ahmad A, Campolo M, Esposito E, Cuzzocrea S.
CNS Neurol Disord Drug Targets. 2013 Nov;12(7):989-1001.

21.
Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.
Skaper SD, Facci L, Giusti P.
Mol Neurobiol. 2013 Oct;48(2):340-52. doi: 10.1007/s12035-013-8487-6. Epub 2013 Jun 28.

22.
Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity.
Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerdle B.
Pain. 2013 Sep;154(9):1649-58. doi: 10.1016/j.pain.2013.05.002. Epub 2013 May 14.

23.
Occipital Neuralgia Responding to Palmitoylethanolamide.
Calabrò RS, Bramanti P.
Headache. 2013 May 23. doi: 10.1111/head.12136. [Epub ahead of print] No abstract available.

24.
Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study.
Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y.
Mol Psychiatry. 2013 Sep;18(9):1034-40. doi: 10.1038/mp.2013.61. Epub 2013 May 14.

25.
Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder.
Hauer D, Schelling G, Gola H, Campolongo P, Morath J, Roozendaal B, Hamuni G, Karabatsiakis A, Atsak P, Vogeser M, Kolassa IT.
PLoS One. 2013 May 7;8(5):e62741. doi: 10.1371/journal.pone.0062741. Print 2013.

26.
Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.
Keppel Hesselink JM, Kopsky DJ.
J Pain Res. 2013 Mar 21;6:239-45. doi: 10.2147/JPR.S42417. Print 2013.

27.
Alterations in the endocannabinoid system in the rat valproic acid model of autism.
Kerr DM, Downey L, Conboy M, Finn DP, Roche M.
Behav Brain Res. 2013 Jul 15;249:124-32. doi: 10.1016/j.bbr.2013.04.043. Epub 2013 May 1.

28.
Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study.
Abdulnour J, Yasari S, Rabasa-Lhoret R, Faraj M, Petrosino S, Piscitelli F, Prud’ Homme D, Di Marzo V.
Obesity (Silver Spring). 2013 Apr 24. doi: 10.1002/oby.20498. [Epub ahead of print]

29.
Emerging neuroprotective effects of N-palmitoylethanolamide besides its significant antinociceptive effects.
Kapoor S.
Pain Med. 2013 May;14(5):773-4. doi: 10.1111/pme.12118. Epub 2013 Apr 12. No abstract available.

30.
Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism.
Descalzi F, Ulivi V, Cancedda R, Piscitelli F, Luongo L, Guida F, Gatta L, Maione S, Di Marzo V.
Tissue Eng Part A. 2013 Oct;19(19-20):2120-9. doi: 10.1089/ten.TEA.2012.0557. Epub 2013 Jun 6.

31.
Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B, Di Marzo V.
PLoS One. 2013;8(4):e60040. doi: 10.1371/journal.pone.0060040. Epub 2013 Apr 3.

32.
Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.
Di Cesare Mannelli L, D’Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A.
Mediators Inflamm. 2013;2013:328797. doi: 10.1155/2013/328797. Epub 2013 Feb 25.

33.
[Administration of MICRONIZED PALMITOYLETHANOLAMIDE (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results.]
Lo Monte G, Soave I, Marci R.
Minerva Ginecol. 2013 Mar 13. [Epub ahead of print] Italian.

34.
Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways.
Ueda N, Tsuboi K, Uyama T.
FEBS J. 2013 May;280(9):1874-94. doi: 10.1111/febs.12152. Epub 2013 Feb 21. Review.

35.
The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain.
Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R.
Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):209-13. doi: 10.1016/j.ejogrb.2013.01.009. Epub 2013 Feb 14.

36.
Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats.
Rea K, Olango WM, Harhen B, Kerr DM, Galligan R, Fitzgerald S, Moore M, Roche M, Finn DP.
Pain. 2013 Apr;154(4):576-85. doi: 10.1016/j.pain.2012.12.021. Epub 2012 Dec 31.

37.
Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normal-weight individuals.
Tomassini Barbarossa I, Carta G, Murru E, Melis M, Zonza A, Vacca C, Muroni P, Di Marzo V, Banni S.
Nutrition. 2013 Mar;29(3):531-6. doi: 10.1016/j.nut.2012.09.018.

38.
Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions.
Balvers MG, Verhoeckx KC, Meijerink J, Wortelboer HM, Witkamp RF.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):23-33.

39.
Biosynthetic pathways of bioactive N-acylethanolamines in brain.
Tsuboi K, Ikematsu N, Uyama T, Deutsch DG, Tokumura A, Ueda N.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):7-16.

40.
Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer’s disease.
Scuderi C, Steardo L.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):62-9.

41.
Physiological role of peroxisome proliferator-activated receptors type alpha on dopamine systems.
Melis M, Carta G, Pistis M, Banni S.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):70-7.

42.
Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice.
Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):45-54.

43.
New insights in mast cell modulation by palmitoylethanolamide.
De Filippis D, Negro L, Vaia M, Cinelli MP, Iuvone T.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):78-83.

44.
Effect of diet on tissue levels of palmitoylethanolamide.
Hansen HS.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):17-25.

45.
Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator.
di Marzo V, Skaper SD.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):4-6. No abstract available.

46.
Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries.
Esposito E, Cuzzocrea S.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):55-61.

47.
Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide.
Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B.
CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):34-44.

48.
Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.
Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S.
J Neuroinflammation. 2013 Feb 1;10:20. doi: 10.1186/1742-2094-10-20.

49.
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.
Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, Pertwee R, Coppola D, Vassallo L, Orlando P, Di Marzo V, Izzo A.
Br J Pharmacol. 2013 May;169(1):213-29. doi: 10.1111/bph.12120.

50.
Elevated anandamide and related N-acylethanolamine levels occur in the peripheral blood of women with ectopic pregnancy and are mirrored by changes in peripheral fatty acid amide hydrolase activity.
Gebeh AK, Willets JM, Bari M, Hirst RA, Marczylo TH, Taylor AH, Maccarrone M, Konje JC.
J Clin Endocrinol Metab. 2013 Mar;98(3):1226-34. doi: 10.1210/jc.2012-3390. Epub 2013 Jan 31.

51.
Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation.
Murina F, Graziottin A, Felice R, Radici G, Tognocchi C.
J Low Genit Tract Dis. 2013 Apr;17(2):111-6. doi: 10.1097/LGT.0b013e3182652316.

52.
N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia.
Taylor BK.
Pain. 2013 Mar;154(3):326-7. doi: 10.1016/j.pain.2012.12.012. Epub 2012 Dec 28. No abstract available.

53.
Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study.
Strobbe E, Cellini M, Campos EC.
Invest Ophthalmol Vis Sci. 2013 Feb 1;54(2):968-73. doi: 10.1167/iovs.12-10899.

54.
CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR, Resende LC, Guzzo LS, Duarte ID.
Anesth Analg. 2013 Feb;116(2):463-72. doi: 10.1213/ANE.0b013e3182707859. Epub 2013 Jan 9.

55.
Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice.
Lenglet S, Thomas A, Soehnlein O, Montecucco F, Burger F, Pelli G, Galan K, Cravatt B, Staub C, Steffens S.
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):215-23. doi: 10.1161/ATVBAHA.112.300275. Epub 2012 Dec 13.

56.
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M, Bertorelli R, Reggiani A, Piomelli D.
Pain. 2013 Mar;154(3):350-60. doi: 10.1016/j.pain.2012.10.018. Epub 2012 Nov 2.

57.
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy.
Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, Russo R, D’Agostino G, Petrosino S, Guida F, Gatta L, van Luijtelaar G, Maione S, Di Marzo V, Calignano A, De Sarro G.

58.
Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Romero TR, Pacheco Dda F, Duarte ID.
Life Sci. 2013 May 2;92(14-16):815-20. doi: 10.1016/j.lfs.2012.10.006. Epub 2012 Oct 30.

59.
Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide.
Ambrosino P, Soldovieri MV, Russo C, Taglialatela M.
Br J Pharmacol. 2013 Mar;168(6):1430-44. doi: 10.1111/bph.12029.

60.
Temporal changes in N-acylethanolamine content and metabolism throughout the peri-adolescent period.
Lee TT, Hill MN, Hillard CJ, Gorzalka BB.
Synapse. 2013 Jan;67(1):4-10. doi: 10.1002/syn.21609. Epub 2012 Oct 4.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: